How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

501. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. (Abstract)

Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. Famciclovir, the well absorbed oral pro-drug of penciclovir, is effective in the treatment of herpes zoster when given three times daily. Because the intracellular half-life of penciclovir triphosphate in varicella-zoster virus (VZV)-infected cells (7h) is considerably longer than that of aciclovir (...) triphosphate (1h), it may be possible to administer famciclovir less frequently than three times daily for herpes zoster: aciclovir is administered five times daily.559 immunocompetent adults presenting with herpes zoster whose skin lesions were present for less than 72 h were randomized to receive famciclovir 750 mg once daily (od), 500 mg twice daily (bid), or 250 mg three times daily (tid), or aciclovir 800 mg five times daily. All treatments were given for 7 days. Participants were evaluated until

2004 Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology Controlled trial quality: uncertain

502. Randomized double-blinded, placebo-controlled clinical trial of famciclovir for reduction of Ménière's disease symptoms. (Abstract)

Randomized double-blinded, placebo-controlled clinical trial of famciclovir for reduction of Ménière's disease symptoms. To conduct a clinical trial of famciclovir for symptom control in Meniere's disease.Randomized, double-blinded placebo-controlled clinical trial in a tertiary referral center, with 12 subjects in the active treatment arm and 11 subjects in the placebo arm.There were no serious adverse events. Twenty-five percent of the famciclovir group and 18% of the placebo group showed (...) a reduction in number of vertigo spells, the primary efficacy endpoint. This difference was not statistically significant. All subjects improved in dizziness and health-related quality of life. There was a trend for the famciclovir arm to have less fluctuation in hearing relative to the placebo arm.No dramatic effects of famciclovir were found on vertigo or dizziness. Some promising effects on reduction of the fluctuation in hearing were observed.Famciclovir may suppress the fluctuation of hearing

2004 Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery Controlled trial quality: predicted high

503. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. Full Text available with Trip Pro

Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. Genital herpes is most often transmitted while the patient is asymptomatic, presumably during episodes of viral shedding. To determine whether famciclovir is effective in reducing asymptomatic shedding, women with frequent, recurrent genital outbreaks were enrolled in a randomized (...) , double-blind, double-dummy, placebo-controlled, parallel-group, 112-day trial of suppressive treatment with famciclovir for anogenital viral shedding. Sixty women received 125 mg of famciclovir 3 times daily, 59 received 250 mg of famciclovir 3 times daily, and 58 received placebo. Patients recorded symptoms and self-obtained cultures daily. Famciclovir reduced asymptomatic shedding, compared with placebo (P < .0001). The onset of asymptomatic shedding was also delayed (P < .0001). Famciclovir

2004 The Journal of infectious diseases Controlled trial quality: predicted high

504. Famciclovir for the treatment of recurrent genital and labial herpes lesions. (Abstract)

Famciclovir for the treatment of recurrent genital and labial herpes lesions. Famciclovir (Famvir, Novartis) is an effective treatment for herpes zoster and herpes simplex. Two separate studies recently examined the effectiveness of single high doses of famciclovir for treating recurrent genital herpes and labial herpes (cold sores). In the randomized, placebo-controlled studies, patients initiated treatment at the first onset of symptoms. For the treatment of genital herpes, a 1,000 mg b.i.d (...) . dose of famciclovir had significant advantages over the placebo, reducing the time required to heal the lesions, preventing the development of lesions beyond the papule stage, and improving the time to resolution of all symptoms. For the treatment of labial herpes, a single 1,500 mg dose of famciclovir shortened the lesion healing time, shortened the time to normal skin, and resulted in faster resolution of pain and tenderness.

2006 Skin therapy letter

505. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. (Abstract)

Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. To investigate penciclovir pharmacokinetics following single and multiple oral administrations of famciclovir to cats.8 adult cats.A balanced crossover design was used. Phase I consisted of a single administration (62.5 mg, PO) of famciclovir. Phase II consisted of multiple doses of famciclovir (62.5 mg, PO) given every 8 or 12 hours for 3 days. Plasma penciclovir concentrations were assayed via (...) liquid chromatography-mass spectrometry at fixed time points after famciclovir administration.Following a single dose of famciclovir, the dose-normalized (15 mg/kg) maximum concentration (C(max)) of penciclovir (350 +/- 180 ng/mL) occurred at 4.6 +/- 1.8 hours and mean +/- SD apparent elimination half-life was 3.1 +/- 0.9 hours. However, the dose-normalized area under the plasma penciclovir concentration-time curve extrapolated to infinity (AUC(0-->)) during phase I decreased with increasing dose

2007 American journal of veterinary research Controlled trial quality: uncertain

506. Famciclovir substitution for patients with acyclovir-associated renal toxicity. (Abstract)

Famciclovir substitution for patients with acyclovir-associated renal toxicity. Acyclovir-induced nephrotoxicity is well known, but published literature lacks information on the safety of substitution with other antiviral agents. We describe four patients with acyclovir-induced renal toxicity that were subsequently managed with hydration and famciclovir. All four patients subsequently had improvements in their symptoms with full recovery of their baseline renal function.

2008 Journal of Infection

507. The Effect of Famciclovir on Delayed Facial Paralysis After Acoustic Tumor Resection. (Abstract)

The Effect of Famciclovir on Delayed Facial Paralysis After Acoustic Tumor Resection. To determine the efficacy of prophylactic famciclovir to significantly reduce the percentage of patients experiencing postoperative delayed facial paresis.Prospective evaluation of facial nerve grade for two groups (treated and untreated) with famciclovir before and after surgery. All procedures were conducted by the same group of experienced neurotologists.In a tertiary neurotologic private practice (...) , the percentage of 1,023 patients with delayed facial paresis after undergoing microsurgical removal of unilateral acoustic tumor with no preoperative treatment was compared to the percentage of 530 patients with preoperative famciclovir treatment. Patients were prescribed famciclovir 500 mg BID for 3 days before surgery and 5 days postoperative. The House-Brackmann Facial Nerve Grade was assessed prospectively at preoperative, immediate postoperative, and discharge from the hospital in both groups.Twenty

2008 Laryngoscope

508. Valacyclovir and famciclovir therapy in herpes zoster. (Abstract)

Valacyclovir and famciclovir therapy in herpes zoster. 12359099 2003 01 13 2018 11 30 1528-4042 2 6 2002 Nov Current neurology and neuroscience reports Curr Neurol Neurosci Rep Valacyclovir and famciclovir therapy in herpes zoster. 477-8 Jubelt Burk B eng Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial United States Curr Neurol Neurosci Rep 100931790 1528-4042 0 Antiviral Agents 452-06-2 2-Aminopurine HG18B9YRS7 Valine MZ1IW7Q79D Valacyclovir (...) QIC03ANI02 Famciclovir X4HES1O11F Acyclovir IM 2-Aminopurine adverse effects analogs & derivatives therapeutic use Acyclovir adverse effects analogs & derivatives therapeutic use Aged Antiviral Agents adverse effects therapeutic use Double-Blind Method Famciclovir Gastrointestinal Diseases chemically induced Headache chemically induced Herpes Zoster complications drug therapy Humans Middle Aged Nausea chemically induced Neuralgia etiology prevention & control Pain etiology prevention & control

2003 Current neurology and neuroscience reports Controlled trial quality: uncertain

509. Should we offer famciclovir to patients with new-onset herpes zoster? (Abstract)

Should we offer famciclovir to patients with new-onset herpes zoster? 10349063 1999 06 14 2018 12 01 0008-350X 45 1999 May Canadian family physician Medecin de famille canadien Can Fam Physician Should we offer famciclovir to patients with new-onset herpes zoster? 1195-6 Martin F F Kildonan Medical Centres, Winnipeg, Man. Evans M F MF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Canada Can Fam Physician 0120300 0008-350X 0 Antiviral Agents 0 Placebos 0 (...) Prodrugs 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs & derivatives therapeutic use Acute Disease Age Factors Antiviral Agents administration & dosage therapeutic use Double-Blind Method Evaluation Studies as Topic Famciclovir Herpes Zoster drug therapy Humans Middle Aged Placebos Prodrugs Time Factors 1999 6 1 1999 6 1 0 1 1999 6 1 0 0 ppublish 10349063 PMC2328600 Br J Dermatol. 1987 Oct;117(4):495-501 3314973 Psychosomatics. 1990 Summer;31(3):287-92

1999 Canadian family physician Medecin de famille canadien Controlled trial quality: uncertain

510. Famciclovir for the treatment of herpes zoster. (Abstract)

Famciclovir for the treatment of herpes zoster. 8627199 1996 06 27 2018 11 30 0094-3509 42 4 1996 Apr The Journal of family practice J Fam Pract Famciclovir for the treatment of herpes zoster. 350 Gordon A A eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial United States J Fam Pract 7502590 0094-3509 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir AIM IM 2-Aminopurine analogs & derivatives therapeutic use Acute Disease Adult Antiviral Agents (...) therapeutic use Double-Blind Method Famciclovir Herpes Zoster complications drug therapy Herpesvirus 3, Human drug effects Humans Neuralgia drug therapy etiology prevention & control Treatment Outcome 1996 4 1 1996 4 1 0 1 1996 4 1 0 0 ppublish 8627199

1996 The Journal of family practice Controlled trial quality: uncertain

511. Famciclovir effective in suppressing recurrent genital herpes. (Abstract)

Famciclovir effective in suppressing recurrent genital herpes. 11361692 1997 05 08 2018 11 30 1087-2914 10 2 1996 Apr AIDS patient care and STDs AIDS Patient Care STDS Famciclovir effective in suppressing recurrent genital herpes. 130 eng Clinical Trial News Randomized Controlled Trial United States AIDS Patient Care STDS 9607225 1087-2914 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir X 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic use (...) Double-Blind Method Famciclovir Herpes Genitalis drug therapy Humans Recurrence 1996 4 1 0 0 2001 5 22 10 1 1996 4 1 0 0 ppublish 11361692

1997 AIDS patient care and STDs Controlled trial quality: uncertain

512. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Full Text available with Trip Pro

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. A mouse model of herpes simplex virus type 1 infection in an immunocompromised host was established by using cyclosporin-A to impair T-cell function. Following inoculation of herpes simplex virus type 1 into the skin of the ear pinna, cyclosporin-A prolonged virus replication in the skin and neural tissues compared with that in immunocompetent mice. This model (...) was used to investigate the activity of famciclovir (FCV) and valaciclovir (VACV), which are oral products of the antiherpesvirus agents penciclovir and acyclovir, respectively. Both prodrugs gave similar blood profiles of the antiherpesvirus agents in normal and cyclosporin-treated mice. The compounds were administered by the oral route at 50 mg/kg per dose twice daily for 5 days. Both compounds were very effective at clearing infectious virus from the tissues despite the immunosuppression; FCV

1995 Antimicrobial Agents and Chemotherapy

513. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Full Text available with Trip Pro

Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. The limited oral absorption in rodents of the antiherpesvirus agent 9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine (BRL 39123 [penciclovir; British approved name]) prompted a search for oral prodrugs. The 6-deoxy derivative of penciclovir (BRL 42359) and the corresponding diacetyl and dipropionyl 6-deoxy derivatives (BRL 42810 [famciclovir (...) ; British approved name] and BRL 43599) were tested as oral prodrugs. The in vivo absorption (dose, 0.2 mmol/kg) and the conversion to the active compound, penciclovir, were determined in rats. Compared with the sodium salt of penciclovir given intravenously, the bioavailabilities of penciclovir from orally administered penciclovir, BRL 42359, famciclovir, and BRL 43599 were 1.5, 9, 41, and 27%, respectively. These prodrugs and 6-deoxyacyclovir were tested for stability in rat duodenal contents

1989 Antimicrobial Agents and Chemotherapy

514. Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study Full Text available with Trip Pro

Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study Famciclovir (FCV) and valaciclovir (VACV) have previously been shown to be potent inhibitors of herpes simplex virus type 1 (HSV-1) in a murine cutaneous model. In the present study, mice were inoculated in the skin of the left ear pinna with herpes simplex virus (HSV) type 1. Antiviral therapy was started on different days postinoculation (p.i.), terminating at the end

1998 Antimicrobial Agents and Chemotherapy

515. Famciclovir (FAMVIR®) Full Text available with Trip Pro

Famciclovir (FAMVIR®) Famciclovir is an antiviral with efficacy and safety comparable to aciclovir, but famciclovir's more favorable pharmacokinetic profile enables a less frequent dosing regimen. Future trials will likely determine famciclovir's role in the suppression of HBV.

1997 Infectious diseases in obstetrics and gynecology

516. Safety of famciclovir in patients with herpes zoster and genital herpes. Full Text available with Trip Pro

Safety of famciclovir in patients with herpes zoster and genital herpes. Safety reporting from individual ongoing and completed clinical studies has demonstrated that famciclovir, the well-absorbed oral form of the antiherpesvirus agent penciclovir, has been well tolerated by more than 3,000 individuals worldwide. An integrated safety evaluation has been performed and includes over 1,600 patients from 11 completed, randomized, double-blind clinical trials and 2 open trials. The famciclovir (...) population consisted of 816 herpes zoster patients (four trials), 409 patients with acute genital herpesvirus infections (seven trials), and 382 patients from two genital herpes suppression studies. Overall, the famciclovir-treated patient population was 57.7% female and ranged in age from 15 to 102 years (mean, 42.6 years), with 31.2% aged 50 years or more and 15.7% aged 65 years or more. The mean duration of exposure to famciclovir was 28.8 days (5.8 days excluding suppression studies). The total daily

1994 Antimicrobial agents and chemotherapy Controlled trial quality: uncertain

517. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. (Abstract)

Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. Twenty healthy male volunteers received single oral doses of famciclovir (125-750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma (...) concentrations of penciclovir were obtained at median times of 0.5-0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (Cmax) increased linearly with dose of famciclovir. Time to Cmax, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects

1994 The Journal of antimicrobial chemotherapy Controlled trial quality: uncertain

518. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. (Abstract)

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. This multicentre, double-blind, double-dummy, randomised study was undertaken to compare the efficacy and tolerability of famciclovir administered at 250 mg, 500 mg and 750 mg three times daily with acyclovir 800 mg five times daily for the treatment of acute uncomplicated herpes zoster (...) in immunocompetent adults. A total of 545 patients participated in this trial. Treatment was initiated within 72 h of the onset of the zoster rash and was continued for seven days. When treatment was initiated within 72 h, famciclovir was found to be as effective as acyclovir at all dose levels for cutaneous lesion healing as demonstrated by the median times to full crusting, cessation of new lesion formation, loss of vesicles and loss of crusts; time to loss of acute pain was comparable in patients receiving

1994 International journal of antimicrobial agents Controlled trial quality: uncertain

519. Efficacy of famciclovir in the treatment of herpes zoster. (Abstract)

Efficacy of famciclovir in the treatment of herpes zoster. Although vidarabine was the first systemic antiviral drug for the treatment of acute herpes zoster, the agent now used most frequently is acyclovir, a far safer drug that became available a decade ago. However, even with widespread use of acyclovir, postherpetic neuralgia (PHN) remains a principal cause of postinfectious morbidity. Newer antiviral agents, such as famciclovir and valacyclovir, have recently been introduced (...) for the treatment of uncomplicated herpes zoster. In a double-blind, randomized study, 500 mg of famciclovir three times daily for 7 days was compared with placebo; in a second study, 500 mg of famciclovir three times daily for 7 days was compared with 800 mg of acyclovir five times daily for 7 days. Famciclovir significantly reduced duration of viral shedding (P = 0.0001) and accelerated lesion resolution compared with placebo. Famciclovir was comparable to acyclovir for these acute parameters. Most

1996 Seminars in dermatology Controlled trial quality: uncertain

520. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. (Abstract)

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

1996 Journal of viral hepatitis Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>